|View Video Online|
Prof. Roberts discussed how the FDA's approval of the first race-specific drug has generated a heated debate about the scientific and political efficacy of race-based medicine. She placed this debate in the context of health disparities and genetic concepts of race, and explored why marketing pharmaceuticals on the basis of race is more likely to worsen racial inequities than cure them. Recognizing that race-based medicine raises both medical and political questions, Roberts rejected the dichotomy often claimed by its promoters that we must put aside social justice concerns in order to improve minority health.
Prof. Roberts was interviewed by Kerri Miller on Minnesota Public Radio's Midmorning – listen here.
Read the related article from the Minnesota Journal of Law, Science & Technology.
The Deinard Memorial Lecture on Law & Medicine is co-sponsored by the University of Minnesota's Joint Degree Program in Law, Health & the Life Sciences and the Center for Bioethics.